undamentalytics Newsletter
Sign in

Upstream Bio, Inc. revenue

Upstream Bio, Inc.'s revenue was $2.9m in fiscal 2025, up 20.4% on the year before. Over the last twelve months it was $3.2m.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue2,3802,3702,8543,158
Growth on the year before—−0.4%+20.4%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Upstream Bio, Inc. $3.2m 16.0% —
Xenetic Biosciences, Inc. $3.3m 33.3% 14.7%
Aligos Therapeutics, Inc. $3.7m 19.4% -5.5%
Dyadic International Inc $3.8m -8.0% 3.4%
DBV Technologies S.a. $3.8m -31.6% -11.6%
Vistagen Therapeutics, Inc. $2.5m 287.3% —

Compare with peers

Head to head: UPB vs XBIOALGS vs UPBDYAI vs UPBUPB vs VTGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Upstream Bio, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Upstream Bio, Inc.